Twenty-two patients (18 female and four male) with duct carcinoma of the breast were selected from the Department of Pathology, National Cancer Institute, Cairo University. The diagnosis was based on the recent WHO classification. Some of the well-characterized biomarkers used for the assessment of breast cancer were used: the hormonal receptor status (ER and PR status), which is used for patients candidate for hormonal therapy; the Her-2/neu status, which is important for herceptin therapy; and TOP2A, which is a therapeutic target for anthracycline treatment.
The mean age of SBC patients was 52.5 years, which is comparable to that in other reports 23,24; however, this figure is slightly lower than that report in other studies from Western countries 25,26. The mean age of FBC patients was 49.5 years, which is slightly lower than that in other reports 27,28; this could be explained by considering breast cancer in Egyptian patients (both SBC and FBC) as a biologically more aggressive disease compared with what has been encountered in western studies 24. The frequency of premenopausal women was higher among FBC patients than in SBC patients, whereas the frequency of postmenopausal women was higher among SBC patients than in FBC patients. These results are similar to those reported in other studies 27–29 but are in contrast to those reported by D’Eredita et al.28, who reported no difference between FBC and SBC patients.
There was a statistically significant difference as regards tumor size between the two groups, with a larger tumor size observed among FBC patients, which is in accordance with the results of some studies 28,29 but is in contrast with those of others 27–30 who found no significant difference between the two groups. A highly significant difference was observed between the two groups as regards tumor grade, with a higher grade among FBC patients, which confirms the presence of more aggressive tumors among patients with a genetic predisposition. These results are in accordance with those of some studies 29,30 but are in contrast with those of another study 28 in which no significant difference between the two groups was found. There was no significant difference between FBC and SBC patients as regards the lymph node status, which is in agreement with the results of other studies 28–30 but is in contrast with the study by Veronesi et al.29, who reported that FBC patients tended to have positive lymph node affection.
There was a highly significant difference among FBC and SBC patients, with a lower ER expression in the FBC group (P=0.001). Other studies have also shown low levels of ER expression in FBC patients 29–31. It is known that ER expression is inversely correlated with tumor grade 32: FBC patients who showed a higher tumor grade than SBC patients would therefore be predicted to be more ER negative. There was a significant difference between FBC and SBC patients (P=0.02) as regards the expression of PR, with a lower expression among FBC patients compared with SBC patients (25 vs. 50%); these results are in accordance with those of other studies 29,30–33. As regards Her-2/neu protein expression, the incidence of its expression in FBC patients (33.3%) compared with SBC patients (30%) showed no statistical difference (P=1.00), which is in agreement with the results of other studies 31–33.
Finally, we conclude that FBC tumors seem to be more aggressive compared with SBC tumors. Our study suggests that TOP2A gene amplification seems to occur in both FBCs and SBCs, however with a higher frequency in FBCs, together with the finding that TOP2A gene amplification may occur independent of Her-2/neu amplification. Thus, we suggest this parameter be determined on a routine basis in patients with breast cancer in general, and especially when FBC is suspected. Moreover, a combined approach using IHC and FISH can optimize Her-2/neu testing for breast carcinoma patients, especially in patients with IHC-equivocal tumors.
There are no conflicts of interest.
1. Parkin DM, Bray F, Ferlay J, Pisani P.Estimating the world cancer burden: globocan.Int J Cancer2001;94:153–156.
2. Mokhtar N, Gouda I, Adel I.Cancer pathology registry 2003–2004 and time trend analysis2007.Egypt:National Cancer Institute, Cairo University.
3. Cannon-Albright LA, Skolnick MH.The genetics of familial breast cancer.Semin Oncol1996;23:1–5.
4. Studzinski G, Harrison LWilliam L, Donegan MD, John S..Genetic basis for the emergence and progression of breast cancer (chapter 10).Cancer of the breast2002:5th ed.Elsevier Science;169–179.
5. Tan DS, Marchió C, Jones RL, Savage K, Smith IE, Dowsett M, Reis-Filho JS.Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline treated patients.Breast cancer Res Treat2008;111:27–44.
6. Wooster R, Weber B.Genomic medicine: breast and ovarian cancer.N Engl J Med2003;348:2339–2347.
7. Yarden Y.Biology of HER2 and its importance in breast cancer.Oncology2001;61Suppl 21–13.
8. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al..Use of a monoclonal antibody against Her-2/neu for metastatic breast cancer that over-expresses Her-2/neu.N Engl J Med2001;344:783–792.
9. Jarvinen TAH, Liu ET.Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes – molecular basis for combination chemotherapy in cancer.Curr Cancer Drug Targets2006;6:579–602.
10. Kenemans P, Verstraeten RA, Verheijen RHM.Oncogenic pathways in hereditary and sporadic breast cancer.Maturitas2004;49:34–43.
11. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al..Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years adjuvant therapy for breast cancer.Lancet2005;365:60–62.
12. Piechocki MP, Yoo GH, Dibbley SK, Lonardo F.Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.Cancer Res2007;67:6825–6843.
13. O’Malley FP, Chai S, Tu D, Shepherd LE, Levinen MN, Bramwell VH, et al..Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.J Natl Cancer Inst2009;101:644–650.
14. Lynch HT, Watson P, Conway TA, Lynch JF.Clinical genetic features in hereditary breast cancer.Breast cancer Res Treat1990;15:63–71.
15. Tavassoli FA, Devilee P.World Health Organization classification of tumors.Pathology and genetics of tumors of the breast and female genital organs2003.Lyon:IARC Press.
16. Elston E, Ellis IO.The breast1998;Vol. 13NY:Churchill Livingstone;365.
17. .AJCC cancer staging handbook from the AJCC cancer staging manual2002:6th ed..New York, NY:Springer-Verlag;257–281.
18. Allred DC, Harvey JM, Berardo M, Clark GM.Prognostic and predictive factors in breast cancer by immunohistochemical analysis.Mod Pathol1998;11:155–168.
19. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ.Specificity of Hercep test in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-Approved Scoring system.J Clin Oncol1999;17:1983–1987.
20. Pinkel D, Gray J, Trask B, Vandenengh G, Fusoce J, Vandekken H.Cytogenetic analysis by in situ hybridization with fluorescently labeled nucleic acid probes.Cold Spring Harb Symp Quant Biol1986;51:151–157.
21. Hagan AI, Bofin AM, Ytterhus B, Maehle LO, Kjellevold KH, Myhre HO, et al..Amplification of TOP2A and Her-2/neu genes in breast cancers occurring in patients harboring BRCA1 germline mutations.Acta Oncol2007;46:199–203.
22. Nielsen KV, Ejlertsen B, Moller S, Jorgensen JT, Knudsen H, Mouridsen HT.The value of TOP2A gene copy number variation as a biomarker in breast cancer: update of DBCG trial 89D.Acta Oncol2008;47:725–734.
23. Omar S, Khaled H, Gaafar R, Zekry AR, Eissa S, El Khatib O.Breast cancer in Egypt: a review of disease presentation and detection strategies.East Mediterr Health J2003;9:448–463.
24. El-Bolkainy MN, Nouh MA, El-Bolkainy TM.Topographic pathology of cancer3rd ed. NCI, Cairo University; 2005. p. 5.
25. Scutt D, Lancaster GA, Manning JT.Breast asymmetry and predisposition to breast cancer.Breast Cancer Res2006;8:R14.
26. Allen-Brady K, Cannon-Albright LA, Neuhausen SL, Camp NJ.A role for XRCC4 in age at diagnosis and breast cancer risk.Cancer Epidemiol Biomarkers Prev2006;15:1306–1310.
27. Espinosa AB, Tabereno MD, Garcíe-Macías MC, Primo D, Bernal AG, Cruz JJ, et al..Her-2/neu gene amplification in familial vs. sporadic breast cancer: impact on the behavior of the disease.Am J Clin Pathol2003;120:917–927.
28. D’Eredita G, Giardina C, Napoli A, Troilo VL, Fuschetti F, Berardi T.Familial and sporadic breast cancers: differences in clinical, histopathological, and immunohistochemical features.Int J Surg Pathol2010;19:724–732.
29. Veronesi U, Boyle P, Goldhirsch A.Familial breast cancer: characteristic and outcome of BRCA1-2 positive and negative cases.Lancet2005;365:17237–1741.
30. Grushko TA, Blackwood MA, Schumm PL, Hagos FG, Adeyanju MO, Feldman MD, et al..Molecular cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers.Cancer Res2002;62:1481–1488.
31. Robson M, Rajan P, Rosen PP, Gilewski T, Hirschaut Y, Pressman P, et al..BRCA-associated breast cancer: absence of a characteristic immunophenotype.Cancer Res1998;58:1839–1842.
32. Osin P, Lakhani S.The pathology of familial breast cancer; immunohistochemistry and molecular analysis.Breast Cancer Res1999;1:36–40.
33. Armes JE, Trute L, White D, Southey MC, Hammet F, Tesoriero A, et al..Distinct molecular pathogenesis of early onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population based study.Cancer Res1999;59:2011–2017.
34. Soomoro S, Shousha S, Taylor P, Shepard HM, Feldman M.c-erbB-2 expression in different histological types of invasive breast carcinoma.J Clin Pathol1991;44:211–214.
35. Ross JS, Slodkowska EA, Symmans S, Pusztai L, Ravdin PM, Hortobagyi GN.The HER-2 receptor and breast cancer: ten years of targeted anti-HER2 therapy and personalized medicine.Oncologist2009;14:320–368.
36. Gancberg D, Lespagnard L, Rouas G, Paesmans M, Piccart M, Di Leo A, et al..Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases.Am J Clin Pathol2000;113:675–682.
37. Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF.The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.J Clin Oncol2002;20:2310–2318.
38. Park K, Kim J, Lim S, Han S.Topoisomerase II-alpha and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy.Eur J Cancer2003;39:631–634.
39. Slamon DJ, Press MF.Alterations in the TOP2A and HER2 genes: association with adjuvant anthracycline sensitivity in human breast cancers.J Natl Cancer Inst2009;101:615–618.
40. Arriola E, Rodriguez-Pinilla SM, Lambros MB, Jones RL, James M, Savage K, et al..Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer.Breast Cancer Res Treat2007;106:181–189.
41. Orlando L, Del Curto B, Gandini S, Ghisini R, Pietri E, Torrisi R, et al..Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline based neoadjuvant chemotherapy in endocrine non responsive Her2/neu-positive breast cancer.Cytopathology2008;17:506–511.
42. Murphy DS, McHardy P, Coutts J, Mallon EA, George WD, Kaye SB, et al..Interphase cytogenetic analysis of ERBB2 and TopoII-alpha co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ.Int J Cancer1995;64:18–26.
43. Jarvinen TA, Tanner M, Barlund M, Borg A, Isola J.Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer.Genes Chromosomes Cancer1999;26:142–150.
44. Hicks DG, Yoder BJ, Pettay J, Swain E, Tarr S, Hartke M, et al..The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2: a flourescence in situ hybridisation study.Hum Pathol2005;36:348–356.
45. Oakman C, Moretti E, Galardi F, Santarpia L, Di Leo A.The role of topoisomerase IIa and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients.Cancer Treat Rev2009;35:662–667.
46. Glynn RW, Miller N, Whelan MC, Kerin MJ.17q12–21 – the pursuit of targeted therapy in breast cancer.Ann Surg Oncol2010;17:1392–1397.
47. Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV.Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.J Clin Oncol2005;23:7483–7490.
48. Petit T, Borel C, Ghnassia J-P, Rodier J-F, Escande A, Mors R, Haegelé P.Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting.Clin Cancer Res2001;7:1577–1581.
49. Coon JS, Marcus E, Gupta-Burt S, Seelig S, Jacobson K, Chen S, et al..Amplification and overexpression of topoisomerase II alpha predict response to anthracycline based therapy in locally advanced breast cancer.Clin Cancer Res2002;8:1061–1067.
50. Wang J, Xu B, Yuan P, Zhang P, Li Q, Ma F, Fan Y.TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy.Breast Cancer Res Treat2012;135:531–537.
51. Fountzilas G, Christodoulou C, Bobos M, Kotoula V, Eleftheraki AG, Xanthakis I, et al..Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab.J Transl Med2012;10:212.
52. Jin L, Wessely O, Marcusson E, Ivan C, Calin G, Alahair SK.Pro-oncogenic factors miR-23b and miR-27b are regulated by Her 2/neu, EGF and TNFα in breast cancer.Cancer Res2013[Epub ahead of print].